Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | NAMPT | P43490 | 8/20 | 0.50 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.49 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.48 |
| ▸ | LSS | P48449 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26099838 | 0.85 | NPC1 (0.55) | NPC1RAB9ANAMPTEPHX2LSS | |
| SCHEMBL23747444 | 0.83 | RAB9A (0.54) | NPC1RAB9ANAMPTEPHX2LSS | |
| SCHEMBL26103091 | 0.83 | RAB9A (0.54) | NPC1RAB9ANAMPTEPHX2LSS | |
| SCHEMBL23747809 | 0.83 | TSHR (0.60) | NPC1RAB9ANAMPTPOLBKMT2A | |
| SCHEMBL26101861 | 0.83 | NAMPT (0.67) | NPC1RAB9ANAMPTLSSPOLB | |
| SCHEMBL23747468 | 0.83 | NAMPT (0.56) | NPC1RAB9ANAMPTEPHX2LSS | |
| SCHEMBL23747808 | 0.83 | RAB9A (0.57) | NPC1RAB9ANAMPTEPHX2LSS | |
| SCHEMBL30361442 | 0.80 | RAB9A (0.54) | NPC1RAB9ANAMPTEPHX2LSS | |
| SCHEMBL26098993 | 0.80 | RAB9A (0.54) | NPC1RAB9ANAMPTEPHX2LSS | |
| SCHEMBL26547007 | 0.79 | NAMPT (0.50) | NPC1RAB9ANAMPTEPHX2LSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
| WO-2021159015-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133132-A1 | NAMPT MODULATORS | NAMPT, MC4R, SIRT1 | NPC1 463/4885RAB9A 807/4885NAMPT 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.